Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidat⦠read more
Healthcare
Biotechnology
3 years
USD
Exclusive to Premium users
$2.14
Price+3.14%
$0.07
$151.637m
Small
-
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$9.034m
-
1y CAGR-
3y CAGR-
5y CAGR-$109.239m
-
1y CAGR-
3y CAGR-
5y CAGR-$1.48
-
1y CAGR-
3y CAGR-
5y CAGR$357.668m
$448.312m
Assets$90.644m
Liabilities$78.542m
Debt17.5%
-0.6x
Debt to EBITDA-$100.197m
-
1y CAGR-
3y CAGR-
5y CAGR